Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal

Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine. 

The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 available patients from previous study with the Company’s leading therapeutic HIV vaccine candidate Vacc-4x.  The study demonstrated that it is possible to elicit strong memory immune responses up to 7 years after the initial vaccination. 

 

 

If you would like to read more, visit Bionor Pharam's website here.

Associated companies:


Related news

Latest news

Vestdavit agrees dive boat cooperation with Hukkelberg

Opportunities in the offshore market are resurfacing after a long dry spell,

PLAR-4000 plays role in NZ seamanship excellence

The relationship between Vestdavit and Australian-headquartered Antelope Engineering extends back to 2000,

To meet the special duties envisaged,

The PL-3600R davit is equipped with shock absorbers,

Olympic Commander keeps Vestdavit alongside for Med rescue mission

To meet the special duties envisaged,

New After Sales Director on-board

Henric will take responsibility for building up strong,

MAINTENANCE CONTRACT WITH STATOIL TJELDBERGODDEN

Beerenberg has entered into a 7-year contract for ISO and other supporting services at Statoil’s Tjeldbergodden facilities. The contract is running from 1 January 2018.

DNV GL: Standardisation can help enable the digital transformation of shipping

DNV GL’s new position paper focuses on the collection of ship sensor data, 

Industry's preferred pipeline standard gets update by DNV GL

A number of requirements related to linepipe fabrication,

Servogear Hybrid CPP for the World’s First Hybrid Catamarans in Commercial Traffic

Norled AS is one of Norway’s largest ferry and express boat operators.